Legal & General Group
VERV

Legal & General Group’s Verve Therapeutics VERV Stock Holding History

Legal & General Group’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-66,825
Closed -$750K – 3459
2025
Q2 		$750K Buy
66,825
+7,356
+12% +$41.9K ﹤0.01% 2320
2025
Q1 		$272K Sell
59,469
-4,957
-8% -$33.2K ﹤0.01% 2563
2024
Q4 		$363K Buy
64,426
+11,628
+22% +$65.6K ﹤0.01% 2565
2024
Q3 		$256K Hold
52,798
– – ﹤0.01% 2640
2024
Q2 		$258K Sell
52,798
-1,056
-2% -$6.64K ﹤0.01% 2633
2024
Q1 		$715K Buy
53,854
+2,124
+4% +$28.2K ﹤0.01% 2305
2023
Q4 		$721K Buy
51,730
+12,880
+33% +$160K ﹤0.01% 2324
2023
Q3 		$515K Buy
38,850
+5,125
+15% +$82.5K ﹤0.01% 2422
2023
Q2 		$632K Buy
33,725
+19,641
+139% +$327K ﹤0.01% 2384
2023
Q1 		$203K Buy
14,084
+814
+6% +$15.9K ﹤0.01% 2583
2022
Q4 		$257K Buy
13,270
+567
+4% +$15K ﹤0.01% 2520
2022
Q3 		$437K Buy
12,703
+4,918
+63% +$157K ﹤0.01% 2377
2022
Q2 		$119K Buy
7,785
+252
+3% +$3.9K ﹤0.01% 2805
2022
Q1 		$172K Buy
7,533
+1,993
+36% +$57K ﹤0.01% 2723
2021
Q4 		$204K Buy
5,540
+4,054
+273% +$170K ﹤0.01% 2718
2021
Q3 		$70K Buy
+1,486
New +$87.4K ﹤0.01% 2909

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Legal & General Group's VERV Position: Q3 2025 in Review

Legal & General Group sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 66,825 shares — an estimated $750K sold.

Legal & General Group first reported a position in VERV in Q3 2021 and held it in 16 quarters. The position peaked at $750K in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Legal & General Group reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Legal & General Group sold 66,825 Verve Therapeutics shares in Q3 2025, an estimated $750K.
  • Legal & General Group first reported a position in Verve Therapeutics in Q3 2021 and held it in 16 quarters.
  • Legal & General Group's Verve Therapeutics position peaked at $750K in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Legal & General Group's 13F filing for Q3 2025, filed 13 Nov 2025.